Caveolin and cancer: A complex relationship

Membrane Microdomain Signaling: Lipid Rafts in Biology and Medicine

Volumn , Issue , 2005, Pages 161-190

  Liscovitch, Mordechai ^a   Burgermeister, Elke ^a   Jain, Neeru ^a   Ravid, Dana ^a   Shatz, Maria ^a   Tencer, Lilach ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748050505     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1385/1-59259-803-X:161     Document Type: Chapter

References (121)

1. Aldred M. A., Ginn-Pease M. E., Morrison C. D., Popkie A. P., Gimm O., Hoang-Vu C., et al. (2003) Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res. 63, 2864-2871.
2. Anderson R. G. W. (1998) The caveolae membrane system. Annu. Rev. Biochem. 67, 199-225.
3. Bagnoli M., Tomassetti A., Figini M., Flati S., Dolo V., Canevari S., et al. (2000) Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to a-folate receptor overexpression. Oncogene 19, 4754-4763.
4. Bayer-Garner I., Morgan M. and Smoller B. R. (2002) Caveolin expression is common among benign and malignant smooth muscle and adipocyte neoplasms. Mod. Pathol. 15, 1-5.
5. Belanger M. M., Roussel E., and Couet J. (2003) Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells. Anticancer Drugs 14, 281-287.
6. Bender F. C., Reymond M. A., Bron C., and Quest A. F. (2000) Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 60, 5870-5878.
7. Benhar M., Engelberg D., and Levitzki A. (2002) ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 3, 420-425.
8. Bilderback T. R., Grigsby R. J., and Dobrowsky R. T. (1997) Association of p75 (NTR) with caveolin and localization of neurotrophin-induced sphingomyelin hydrolysis to caveolae. J. Biol. Chem. 272, 10, 922-10, 927.
9. Burgermeister E., Tencer L., and Liscovitch M. (2003) Peroxisome proliferatoractivated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene 22, 3888-3900.
10. Cameron P. L., Liu C., Smart D. K., Hantus S. T., Fick J. R., and Cameron R. S. (2002) Caveolin-1 expression is maintained in rat and human astroglioma cell lines. Glia 37, 275-290.
11. Campbell L., Hollins A. J., Al-Eid A., Newman G. R., von Ruhland C., and Gumbleton M. (1999) Caveolin-1 expression and caveolae biogenesis during cell transdifferentiation in lung alveolar epithelial primary cultures. Biochem. Biophys. Res. Commun. 262, 744-751.
12. Cantley L. C. and Neel B. G. (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 96, 4240-4245.
13. Capozza F., Williams T. M., Schubert W., McClain S., Bouzahzah B., Sotgia F., et al. (2003) Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am. J. Pathol. 162, 2029-2039.
14. Cho K. A., Ryu S. J., Park J. S., Jang I. S., Ahn J. S., Kim K. T., et al. (2003) Senescent phenotype can be reversed by reduction of caveolin status. J. Biol. Chem. 278, 27789-27795.
15. Cohen A. W., Park D. S., Woodman S. E., Williams T. M., Chandra M., Shirani J., et al. (2003) Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am. J. Physiol. Cell Physiol. 284, C457-C474.
16. Crnogorac-Jurcevic T., Efthimiou E., Capelli P., Blaveri E., Baron A., Terris B., et al. (2001) Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 20, 7437-7446.
17. Czarny M., Liu J., Oh P., and Schnitzer J. E. (2003) Transient mechanoactivation of neutral sphingomyelinase in caveolae to generate ceramide. J. Biol. Chem. 278, 4424-4430.
18. Davidson B., Nesland J. M., Goldberg I., Kopolovic J., Gotlieb W. H., Bryne M., et al. (2001) Caveolin-1 expression in advanced-stage ovarian carcinoma-a clinicopathologic study. Gynecol. Oncol. 81, 166-171.
19. Drab M., Verkade P., Elger M., Kasper M., Lohn M., Lauterbach B., et al. (2001) Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293, 2449-2452.
20. El-Deiry W. S. (1997) Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr. Opin. Oncol. 9, 79-87.
21. Engelman J. A., Wykoff C. C., Yasuhara S., Song K. S., Okamoto T., and Lisanti M. P. (1997) Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J. Biol. Chem. 272, 16, 374-16, 381.
22. Engelman J. A., Chu C., Lin A., Jo H., Ikezu T., Okamoto T., et al. (1998a). Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett. 428, 205-211.
23. Engelman J. A., Lee R. J., Karnezis A., Bearss D. J., Webster M., Siegel P., et al. (1998b) Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J. Biol. Chem. 273, 20, 448-20, 455.
24. Engelman J. A., Zhang X. L., and Lisanti M. P. (1998c) Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett. 436, 403-410.
25. Engelman J. A., Zhang X. L., and Lisanti M. P. (1999) Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5' promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett. 448, 221-230.
26. Feng X., Gaeta M. L., Madge L. A., Yang J. H., Bradley J. R., and Pober J. S. (2001) Caveolin-1 associates with TRAF2 to form a complex that is recruited to tumor necrosis factor receptors. J. Biol. Chem. 276, 8341-8349.
27. Fielding C. J., Bist A., and Fielding P. E. (1999) Intracellular cholesterol transport in synchronized human skin fibroblasts. Biochemistry 38, 2506-2513.
28. Fielding C. J. and Fielding P. E. (2001) Cholesterol and caveolae: structural and functional relationships. Biochim. Biophys. Acta 1529, 210-222.
29. Fine S. W., Lisanti M. P., Galbiati F., and Li M. (2001) Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am. J. Clin. Pathol. 115, 719-724.
30. Fiucci G., Ravid D., Reich R., and Liscovitch M. (2002) Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21, 2365-2375.
31. Fong A., Garcia E., Gwynn L., Lisanti M. P., Fazzari M. J., and Li M. (2003) Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am. J. Clin. Pathol. 120, 93-100.
32. Fra A. M., Mastroianni N., Mancini M., Pasqualetto E., and Sitia R., (1999) Human caveolin-1 and caveolin-2 are closely linked genes colocalized with WI-5336 in a region of 7q31 frequently deleted in tumors. Genomics 56, 355-356.
33. Fra A. M., Pasqualetto E., Mancini M., and Sitia R. (2000) Genomic organization and transcriptional analysis of the human genes coding for caveolin-1 and caveolin-2. Gene 243, 75-83.
34. Fuchs S., Hollins A. J., Laue M., Schaefer U. F., Roemer K., Gumbleton M., et al. (2003) Differentiation of human alveolar epithelial cells in primary culture: morphological characterization and synthesis of caveolin-1 and surfactant protein-C. Cell Tissue Res. 311, 31-45.
35. Fukumura D., Gohongi T., Kadambi A., Izumi Y., Ang J., Yun C. O., et al. (2001) Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. USA 98, 2604-2609.
36. Galbiati F., Volonte D., Engelman J. A., Watanabe G., Burk R., Pestell R. G., et al. (1998a) Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 17, 6633-6648.
37. Galbiati F., Volonte D., Gil O., Zanazzi G., Salzer J. L., Sargiacomo M., et al. (1998b) Expression of caveolin-1 and -2 in differentiating PC12 cells and dorsal root ganglion neurons: caveolin-2 is up-regulated in response to cell injury. Proc. Natl. Acad. Sci. USA 95, 10, 257-10, 262.
38. Galbiati F., Volonte D., Brown A. M., Weinstein D. E., Ben-Ze'ev A., Pestell R. G., et al. (2000) Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J. Biol. Chem. 275, 23, 368-23, 377.
39. Galbiati F., Razani B., and Lisanti M. P. (2001a) Caveolae and caveolin-3 in muscular dystrophy. Trends Mol. Med. 7, 435-441.
40. Galbiati F., Volonte D., Liu J., Capozza F., Frank P. G., Zhu L., et al. (2001b) Caveolin-1 expression negatively regulates cell cycle progression by inducing G0/G1 arrest via a p53/p21WAF1/Cip1-dependent mechanism. Mol. Biol. Cell 12, 2229-2244.
41. Garrigues A., Escargueil A. E., and Orlowski S. (2002) The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc. Natl. Acad. Sci. USA 99, 10, 347-10, 352.
42. Glenney J. R. J. (1989) Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J. Biol. Chem. 264, 20, 163-20, 166.
43. Glenney J. R. J. and Soppet D. (1992) Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc. Natl. Acad. Sci. USA 89, 10, 517-10, 521.
44. Goligorsky M. S., Li H., Brodsky S., and Chen J. (2002) Relationships between caveolae and eNOS: Everything in proximity and the proximity of everything. Am. J. Physiol. Renal Physiol. 283, F1-F10.
45. Gottesman M. M. (1993) How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 53, 747-754.
46. Gratton J. P., Lin M. I., Yu J., Weiss E. D., Jiang Z. L., Fairchild T. A., et al. (2003) Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 4, 31-39.
47. Hayashi K., Matsuda S., Machida K., Yamamoto T., Fukuda Y., Nimura Y., et al. (2001) Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res. 61, 2361-2364.
48. Ho C. C., Huang P. H., Huang H. Y., Chen Y. H., Yang P. C. and Hsu S. M. (2002) Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am. J. Pathol. 161, 1647-1656.
49. Hulit J., Bash T., Fu M., Galbiati F., Albanese C., Sage D. R., et al. (2000) The cyclin D1 gene is transcriptionally repressed by caveolin-1. J. Biol. Chem. 275, 21, 203-21, 209.
50. Hurlstone A. F., Reid G., Reeves J. R., Fraser J., Strathdee G., Rahilly M., et al. (1999) Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 18, 1881-1890.
51. Ito Y., Yoshida H., Nakano K., Kobayashi K., Yokozawa T., Hirai K., et al. (2002) Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br. J. Cancer 86, 912-916.
52. Kato K., Hida Y., Miyamoto M., Hashida H., Shinohara T., Itoh T., et al. (2002) Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94, 929-933.
53. Kim Y. N., Dam P., and Bertics P. J. (2002) Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: dependence on ErbB1 expression and Src activation. Exp. Cell Res. 280, 134-147.
54. Ko Y. G., Lee J. S., Kang Y. S., Ahn J. H., and Seo J. S. (1999) TNF-alpha-mediated apoptosis is initiated in caveolae-like domains. J. Immunol. 162, 7217-7223.
55. Koleske A. J., Baltimore D., and Lisanti M. P. (1995) Reduction of caveolin and caveolae in oncogenically transformed cells. Proc. Natl. Acad. Sci. USA 92, 1381-1385.
56. Lavie Y., Cao H.-T., Bursten S. L., Giuliano A. E., and Cabot M. C. (1996) Accumulation of glucosylceramides in multidrug-resistant cancer cells. J. Biol. Chem. 271, 19530-19536.
57. Lavie Y., Fiucci G., and Liscovitch M. (1998) Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J. Biol. Chem. 273, 32, 380-32, 383.
58. Lavie Y. and Liscovitch M. (2000) Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconj. J. 17, 253-259.
59. Lee H., Volonte D., Galbiati F., Iyengar P., Lublin D. M., Bregman D. B., et al. (2000) Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: Identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol. Endocrinol. 14, 1750-1775.
60. Lee H., Park D. S., Razani B., Russell R. G., Pestell R. G., and Lisanti M. P. (2002) Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am. J. Pathol. 161, 1357-1369.
61. Lee S. W., Reimer C. L., Oh P., Campbell D. B., and Schnitzer J. E. (1998) Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16, 1391-1397.
62. Li L., Yang G., Ebara S., Satoh T., Nasu Y., Timme T. L., et al. (2001a) Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 61, 4386-4392.
63. Li W. P., Liu P., Pilcher B. K., and Anderson R. G. (2001b) Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. J. Cell Sci. 114, 1397-1408.
64. Lisanti M. P., Scherer P. E., Vidugiriene J., Tang Z., Hermanowski-Vosatka A., Tu Y.-H., et al. (1994) Characterization of caveolin-rich membrane domains isolated from an endothelial rich source: Implications for human disease. J. Cell. Biol. 126, 111-126.
65. Liu J., Oh P., Horner T., Rogers R. A., and Schnitzer J. E. (1997a) Organized endothelial cell surface signal transduction in caveolae distinct from glycosylphosphatidylinositol-anchored protein microdomains. J. Biol. Chem. 272, 7211-7222.
66. Liu J., Lee P., Galbiati F., Kitsis R. N., and Lisanti M. P. (2001) Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. Am. J. Physiol. Cell Physiol. 280, C823-C835.
67. Liu P. and Anderson R. G. W. (1995) Compartmentalized production of ceramide at the cell surface. J. Biol. Chem. 270, 27179-27185.
68. Liu P., Ying Y., and Anderson R. G. (1997b) Platelet-derived growth factor activates mitogen-activated protein kinase in isolated caveolae. Proc. Natl. Acad. Sci. USA 94, 13, 666-13, 670.
69. Liu P., Rudick M., and Anderson R., G. (2002) Multiple functions of caveolin-1. J. Biol. Chem. 277, 41, 295-41, 298.
70. Matsumura I., Kitamura T., Wakao H., Tanaka H., Hashimoto K., Albanese C., et al. (1999) Transcriptional regulation of the cyclin D1 promoter by STAT5: Its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J. 18, 1367-1377.
71. Mikol D. D., Hong H. L., Cheng H. L. and Feldman E. L. (1999) Caveolin-1 expression in Schwann cells. Glia 27, 39-52.
72. Mineo C., James G. L., Smart E. J., and Anderson R. G. W. (1996) Localization of epidermal growth factor-stimulated Ras/Raf-1 interaction to caveolae membrane. J. Biol. Chem. 271, 11930-11935.
73. Morgan M. B., Stevens G. L., Tannenbaum M., and Salup R. (2001) Expression of the caveolins in dermal vascular tumors. J. Cutan. Pathol. 28, 24-28.
74. Nasu Y., Timme T. L., Yang G., Bangma C. H., Li L., Ren C., et al (1998) Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat. Med. 4, 1062-1064.
75. Nestl A., Von Stein O. D., Zatloukal K., Thies W. G., Herrlich P., Hofmann, M., et al. (2001) Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res. 61, 1569-1577.
76. Okamoto T., Schlegel A., Scherer P. E., and Lisanti M. P. (1998) Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J. Biol. Chem. 273, 5419-5422.
77. Park D. S., Lee H., Frank P. G., Razani B., Nguyen A. V., Parlow A. F., et al. (2002) Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade. Mol. Biol. Cell 13, 3416-3430.
78. Perou C. M., Sorlie T., Eisen M. B., van de Rijn M., Jeffrey S. S., Rees C. A., et al. (2000) Molecular portraits of human breast tumours. Nature 406, 747-752.
79. Pflug B. R., Reiter R. E., and Nelson J. B. (1999) Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate 40, 269-273.
80. Podar K., Tai Y. T., Cole C. E., Hideshima T., Sattler M., Hamblin A., et al. (2003) Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J. Biol. Chem. 278, 5794-5801.
81. Racine C., Belanger M., Hirabayashi H., Boucher M., Chakir J., and Couet J. (1999) Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem. Biophys. Res. Commun. 255, 580-586.
82. Rajjayabun P. H., Garg S., Durkan G. C., Charlton R., Robinson M. C., and Mellon J. K. (2001) Caveolin-1 expression is associated with high-grade bladder cancer. Urology 58, 811-814.
83. Razani B., Altschuler Y., Zhu L., Pestell R. G., Mostov K. E., and Lisanti M. P. (2000) Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry 39, 13, 916-13, 924.
84. Razani B., Engelman J. A., Wang X. B., Schubert W., Zhang X. L., Marks C. B., et al. (2001) Caveolin-1 null mice are viable, but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276, 38, 121-38, 138.
85. Razani B., Woodman S. E., and Lisanti M. P. (2002) Caveolae: from cell biology to animal physiology. Pharmacol. Rev. 54, 431-467.
86. Ross D. T., Scherf U., Eisen M. B., Perou C. M., Rees C., Spellman P., et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24, 227-235.
87. Rothberg K. G., Heuser J. E., Donzell W. C., Ying Y. S., Glenney J. R., and Anderson R. G. (1992) Caveolin, a protein component of caveolae membrane coats. Cell 68, 673-682.
88. Sager R., Sheng S., Anisowitz A., Sotiropoulou G., Zhou Z., Stenman G., et al. (1994) RNA genetics of breast cancer: maspin as paradigm. Cold Spring Harb. Symp. Quant. Biol. 59, 537-546.
89. Sallinen S. L., Sallinen P. K., Haapasalo H. K., Helin H. J., Helen P. T., Schraml P., et al. (2000) Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 60, 6617-6622.
90. Sanchez-Carbayo M., Socci N. D., Charytonowicz E., Lu M., Prystowsky M., Childs G., et al. (2002) Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res. 62, 6973-6980.
91. T2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 97, 1225-1233.
92. Scheiffele P., Verkade P., Fra A. M., Virta H., Simons K., and Ikonen E. (1998) Caveolin-1 and -2 in the exocytic pathway of MDCK cells. J. Cell Biol. 140, 795-806.
93. Scherer P. E., Lisanti M. P., Baldini G., Sargiacomo M., Mastick C. C., and Lodish H. F. (1994) Induction of caveolin during adipogenesis and association of GLUT4 with caveolin-rich vesicles. J. Cell Biol. 127, 1233-1243.
94. Scherer P. E., Okamoto T., Chun M., Nishimoto I., Lodish H. F., and Lisanti M. P. (1996) Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. Proc. Natl. Acad. Sci. USA 93, 131-135.
95. Scherer P. E., Lewis R. Y., Volonte D., Engelman J. A., Galbiati F., Couet J., et al. (1997) Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo. J. Biol. Chem. 272, 29, 337-29, 346.
96. Shack S., Wang X. T., Kokkonen G. C., Gorospe M., Longo D. L., and Holbrook N. J. (2003) Caveolin-induced activation of the phosphatidylinositol 3-kinase/Akt pathway increases arsenite cytotoxicity. Mol. Cell. Biol. 23, 2407-2414.
97. Shin S.-I., Freedman V. H., Risser R., and Pollack R. 1975. Tumorigenicity of virustransformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc. Natl. Acad. Sci. USA 72, 4435-4439.
98. Silva W. I., Maldonado H. M., Lisanti M. P., Devellis J., Chompre G., Mayol N., et al. (1999) Identification of caveolae and caveolin in C6 glioma cells. Int. J. Dev. Neurosci. 17, 705-714.
99. Smart E. J., Ying Y. S., Mineo C., and Anderson R. G. (1995) A detergent-free method for purifying caveolae membrane from tissue culture cells. Proc. Natl. Acad. Sci. USA 92, 10, 104-10, 108.
100. Smart E. J., Graf G. A., McNiven M. A., Sessa W. C., Engelman J. A., Scherer P. E., et al. (1999) Caveolins, liquid-ordered domains, and signal transduction. Mol. Cell. Biol. 19, 7289-7304.
101. Song K. S., Scherer P. E., Tang Z., Okamoto T., Li S., Chafel M., et al. (1996) Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J. Biol. Chem. 271, 15, 160-15, 165.
102. Stacey D. W. (2003) Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr. Opin. Cell Biol. 15, 158-163.
103. Suzuoki M., Miyamoto M., Kato K., Hiraoka K., Oshikiri T., Nakakubo Y., et al. (2002) Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br. J. Cancer 87, 1140-1144.
104. Tahir S. A., Yang G., Ebara S., Timme T. L., Satoh T., Li L., et al. (2001) Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 61, 3882-3885.
105. Terris B., Blaveri E., Crnogorac-Jurcevic T., Jones M., Missiaglia E., Ruszniewski P., et al. (2002) Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am. J. Pathol. 160, 1745-1754.
106. Timme T. L., Goltsov A., Tahir S., Li L., Wang J., Ren C., et al. (2000) Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 19, 3256-3265.
107. Tobias E. S., Hurlstone A. F., MacKenzie E., McFarlane R. and Black D. M. (2001) The TES gene at 7q31.1 is methylated in tumours and encodes a novel growthsuppressing LIM domain protein. Oncogene 20, 2844-2853.
108. Veldman R. J., Maestre N., Aduib O. M., Medin J. A., Salvayre R., and Levade T. (2001) A neutral sphingomyelinase resides in sphingolipid-enriched microdomains and is inhibited by the caveolin-scaffolding domain: potential implications in tumour necrosis factor signalling. Biochem. J. 355, 859-868.
109. Volonte D., Zhang K., Lisanti M. P., and Galbiati F. (2002) Expression of caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts. Stress-induced premature senescence upreguates the expression of endogenous caveolin-1. Mol. Biol. Cell 13, 2502-2517.
110. Wiechen K., Diatchenko L., Agoulnik A., Scharff K. M., Schober H., Arlt K., et al. (2001a) Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am. J. Pathol. 159, 1635-1643.
111. Wiechen K., Sers C., Agoulnik A., Arlt K., Dietel M., Schlag P. M., et al. (2001b) Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am. J. Pathol. 158, 833-839.
112. Wikman H., Kettunen E., Seppanen J. K., Karjalainen A., Hollmen J., Anttila S., et al. (2002) Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 21, 5804-5813.
113. Williams T. M., Cheung M. W., Park D. S., Razani B., Cohen A. W., Muller W. J., et al. (2003) Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol. Biol. Cell 14, 1027-1042.
114. Woodman S. E., Ashton A. W., Schubert W., Lee H., Williams T. M., Medina F. A., et al. (2003) Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. Am. J. Pathol. 162, 2059-2068.
115. Yang C.-P. H., Galbiati F., Volonte D., Horwitz S. B., and Lisanti M. P. (1998a) Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett. 439, 368-372.
116. Yang G., Truong L. D., Timme T. L., Ren C., Wheeler T. M., Park S. H., et al. (1998b) Elevated expression of caveolin is associated with prostate and breast cancer. Clin. Cancer Res. 4, 1873-1880.
117. Yang G., Truong L. D., Wheeler T. M., and Thompson T. C. (1999) Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 59, 5719-5723.
118. Zenklusen J. C., Conti C. J,. and Green E. D. (2001) Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31. Nat. Genet. 27, 392-398.
119. Zhang W., Razani B., Altschuler Y., Bouzahzah B., Mostov K. E., Pestell R. G., et al. (2000) Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J. Biol. Chem. 275, 20, 717-20, 725.
120. Zhao Y. Y., Liu Y., Stan R. V., Fan L., Gu Y., Dalton N., Chu, et al. (2002) Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc. Natl. Acad. Sci. USA 99, 11, 375-11, 380.
121. Zundel W., Swiersz L. M., and Giaccia A. (2000) Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Mol. Cell. Biol. 20, 1507-1514.